ERBB2 and breast cancer: Although MetaSite Score was not prognostic in triple negative or HER2+ breast cancer in this cohort, it is noteworthy that the scores were significantly higher in this high-risk subtypes compared with HR+/HER2-negative disease, which is consistent with the hypothesis that higher TMEM Score is associated with greater distant recurrence risk.